|
27 February 2001. The most promising target for an Alzheimer's therapy
in the short term may be the enzyme β-secretase, suggest two papers
in the March issue of Nature Neuroscience. Two separate groups have
found that mice lacking the BACE1 isoform of β-secretase do not
produce amyloid-β. Perhaps more significantly, these transgenic mice
grow to seemingly normal adulthood, suggesting that interfering with the
enzyme in human Alzheimer's patients might not lead to unacceptable
side effects.
Most of the attention in this arena has been paid to
γ-secretase, which is also involved in the production of the
presumed cellular assassin, amyloid-β (Aβ). Both γ- and
β-secretase (as well as α-secretase) cleave the amyloid precursor
protein (APP). Philip Wong, Huaibin Cai, and their associates at Johns
Hopkins, working with cultured embryonic day 16 neurons from BACE1
deficient mice, report that BACE1 cleaves APP at the +1 and +11 sites,
ultimately resulting in the toxic Aβ varieties 1-40/42 and 11-40/42.
Their transgenic mice lacking BACE1 failed to produce these Aβ
varieties, secreting only small amounts of the Aβ17-40 species,
even when human Swedish variant APP, associated with familial
Alzheimer's, was introduced.
These results are echoed by Robert Vassar, Yi Luo, and
associates at Amgen, who determined that brain extracts from two- to three-month-old BACE1-deficient mice lacked any appreciable Aβ of either
the x-40 or x-42 varieties, despite the fact that these mice had been
genetically altered to overproduce APP. Even so, three- to four-month-old
mice revealed no abnormalities on a battery of pathology tests of neural
and nonneural tissues, as well as clinical chemistry analyses. "We found
the viability of BACE1(-/-) mice to be very surprising, because BACE1 is
expressed at low levels in most tissues, and is highly expressed in
brain and pancreas," wrote the authors. This last point is especially
newsworthy because γ-secretase, another prime target for an
Alzheimer's therapy, may be too important to other physiological
functions to allow interference for the sake of abolishing Aβ
production in humans. The fact that BACE1-deficient mice appear normal
up to one year of age is likely to encourage the development of BACE1
inhibitors for trials in Alzheimer's patients.-Hakon Heimer.
Reference:Luo Y, Bolon B, Kahn S, Bennett BD, Babu-Khan S, Denis P, Fan W, Kha H, Zhang J, Gong Y, Martin L, Louis JC, Yan Q, Richards WG, Citron M, Vassar R.Luo Y et al. Mice deficient in BACE1, the Alzheimer's beta-secretase, have normal phenotype and abolished beta-amyloid generation. Nature Neurosci 2001 March;4(3):231-2. Abstract
Cai H, Wang Y, McCarthy D, Wen H, Borchelt DR, Price DL, Wong PC. BACE1 is the major b-secretase for generation of Ab peptides by neurons. Nature Neurosci 2001 March;4(3):233-4. Abstract
|